ImageneBio (IMA) EBITDA Margin (2020 - 2025)

ImageneBio (IMA) posted EBITDA Margin of 749.38% for Q1 2025, down 1188.22% sequentially from 58.17% in Q3 2024.

ImageneBio (IMA) EBITDA Margin (2020 - 2025) Analysis & Trends

ImageneBio has reported EBITDA Margin for 6 years, with the latest figure at 749.38% in Q1 2025.

Quarterly EBITDA Margin changed N/A year-over-year to 749.38% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 845.85% (changed N/A YoY) and the FY2023 annual result came in at 823.33%, down 36934.0% from the prior year.
EBITDA Margin fell to 749.38% in Q1 2025 per IMA's latest filing, from 58.17% in the prior quarter.
Over five years, EBITDA Margin peaked at 13.81% in Q4 2021 and troughed at 5484.55% in Q2 2022.
A 5-year average of 1039.0% and a median of 372.57% in 2021 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2021 and 2022: EBITDA Margin surged 4009535 bps in 2021, then slumped 512707 bps in 2022.
Over 5 years, EBITDA Margin stood at 13.81% in 2021, then sank by 2108 bps to 277.32% in 2022, then tumbled by 1099 bps to 3324.43% in 2023, then jumped by 98 bps to 58.17% in 2024, then slumped by 1188 bps to 749.38% in 2025.
According to Business Quant data, EBITDA Margin over the past three periods registered 749.38%, 58.17%, and 3324.43% for Q1 2025, Q3 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	140.29 Bn	132.43 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.58 Bn	78.58 Bn	3.93 Bn	30.15%
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn	32.54%
4	Moderna	61.87 Bn	56.73 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.18 Bn	37.08 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.51 Bn	28.20 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.90 Bn	10.51 Bn	668.28 Mn	-35.57%
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	19.75%
10	ImageneBio	49.41 Mn	-85.94 Mn	-	-

Download Data